Comparator supply for NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY). Phase: PHASE2, PHASE3. Status: Recruiting. Countries: United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Denmark, France, Greece, Guatemala, Hong Kong, Israel, Italy, Japan, Mexico, New Zealand, Peru, Poland, South Korea, Thailand, Turkey (Türkiye), Ukraine, United Kingdom. Last update posted 2026-10-21.
Registry record: https://clinicaltrials.gov/study/NCT05139017.
Canadian-labelled bendamustine
11 marketed Canadian product(s) from 6 manufacturer(s) contain bendamustine hydrochloride. Available strengths: 100 MG, 25 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled gemcitabine
2 marketed Canadian product(s) from 2 manufacturer(s) contain gemcitabine (gemcitabine hydrochloride). Available strengths: 38 MG, 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled oxaliplatin
5 marketed Canadian product(s) from 5 manufacturer(s) contain oxaliplatin. Available strengths: 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled bendamustine as a trial comparator?
Yes. We source Canadian-marketed bendamustine under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT05139017.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1 (431) 588-9055.